Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 5, 1997, Pages 556-561

  Bronsky, Edwin A ^b   Kemp, James P ^b   Zhang, Ji ^b   Guerreiro, Debra ^b   Reiss, Theodore F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MALE; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREADMILL EXERCISE;

ACETATES; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BRONCHOCONSTRICTION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXERCISE; HUMANS; MIDDLE AGED; QUINOLINES; RECEPTORS, LEUKOTRIENE B4;

EID: 0031430503     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90051-5     Document Type: Article

References (17)

1. Lewis RA, Austen F, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway [review]. N Engl J Med 1990;323:645-55.
2. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-98.
3. Woodward DF, Wichmann BF, Gill CA, Wassermann MA. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 1983;25:131-42.
4. 4 in response to soluble agonists. J Immunol 1991;147:3855-61.
5. 4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol 1995;269:L151-7.
6. 4-receptor antagonist. N Engl J Med 1990;323:1736-9.
7. 4 receptor antagonist in patients with chronic asthma [abstract]. J Allergy Clin Immunol 1991;87:309A.
8. 4-receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
9. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996;275:931-6.
10. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997;61:83-92.
11. 4-receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201.
12. 4-receptor antagonist, inhibits exercise-induced bronchoconstriction at the end of a once-daily dosing interval [abstract]. Am J Respir Crit Care Med 1996; 151(4 pt 2):377.
13. 4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol 1995;40:277-80.
14. Crapo RO, Hankinson JL, Irvin C. Standardization of spirometry. Am J Respir Crit Care Med 1995;152: 1107-36.
15. Silverman M, Konig P, Godfrey S. Use of serial exercise tests to assess the efficacy and duration of action of drugs for asthma. Thorax 1973;28:574-8.
16. 4 receptor antagonist, exhibits a dose related improvement in the once daily treatment of patients with chronic asthma [abstract]. Eur Respir J 1995;8:19.
17. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992;146:358-63.